It's a SMAD/SMAD World

Cullen Taniguchi; Anirban Maitra

doi:10.1016/j.cell.2015.05.030

It's a SMAD/SMAD World

Cell. 2015 Jun 4;161(6):1245-6. doi: 10.1016/j.cell.2015.05.030.

Authors

Cullen Taniguchi¹, Anirban Maitra²

Affiliations

¹ Departments of Radiation Oncology, Experimental Radiation Oncology, and Cancer Biology, UT MD Anderson Cancer Center, Houston, TX, 77030, USA. Electronic address: ctaniguchi@mdanderson.org.
² Departments of Pathology and Translational Molecular Pathology, UT MD Anderson Cancer Center, Houston, TX, 77030, USA.

PMID: 26046433
DOI: 10.1016/j.cell.2015.05.030

Abstract

DPC4/SMAD4 mutations are associated with aggressive pancreatic cancer. In this issue of Cell, Whittle et al. demonstrate that Runx3 expression combined with Dpc4/Smad4 status can predict the metastatic propensity of pancreatic tumors, providing valuable guidance for personalized therapy for patients with pancreatic cancer.

Publication types

Comment

MeSH terms

Animals
Carcinoma, Pancreatic Ductal / metabolism*
Core Binding Factor Alpha 3 Subunit / metabolism*
Humans
Neoplasm Metastasis / genetics*
Pancreatic Neoplasms / metabolism*

Substances

Core Binding Factor Alpha 3 Subunit